The Prediction Potential of the Pretreatment Lung Immune Prognostic Index for the Therapeutic Outcomes of Immune Checkpoint Inhibitors in Patients With Solid Cancer: A Systematic Review and Meta-Analysis

Frontiers in Oncology

Xiao-Yun Yang¹  Zhao-Ru Dong²  Jian-Guo Hong²  Zhi-Qiang Chen²  Hui Liu²  Tao Li³  Xiao-Li Yang⁴ 

[1] Department of Gastroenterology, Qilu Hospital, Shandong University, Jinan, China;Department of General Surgery, Qilu Hospital, Shandong University, Jinan, China;Department of Hepatobiliary Surgery, The Second Hospital of Shandong University, Jinan, China;Department of Nephrology, Jinan Central Hospital, Shandong University, Jinan, China;

关键词: lung immune prognostic index;    immune checkpoint inhibitors;    solid cancer;    chemotherapy;    meta-analysis;   

DOI  :  10.3389/fonc.2021.691002

来源: DOAJ

【 摘 要 】

BackgroundThe lung immune prognostic index (LIPI) is recently developed to predict immune checkpoint inhibitors (ICIs) treatment outcomes for non-small cell lung cancer. However, its predictive value for other types of cancer remained unclear. This meta-analysis aimed to evaluate the association between pretreatment LIPI score and therapeutic outcomes in cancer patients treated with ICIs.MethodsWe searched PubMed, Cochrane Library literature databases and EMBASE for abstracts and full-text articles published from the inception of the database until 16th, Nov 2020. Meta-analyses were performed separately for progression-free survival (PFS) and overall survival (OS) by using the random-effects model.ResultsA total of 12 studies involving 4883 patients receiving ICIs treatment were identified for the primary analysis. The pooled results implied that compared with good LIPI score groups, patients with poor or intermediate LIPI score were significantly associated with worse OS (HR=3.33, 95%CI 2.64-4.21, P < 0.001, I2 = 64.2%; HR=1.71, 95%CI 1.43-2.04, P < 0.001, I2 = 43.6%, respectively) and PFS (HR=2.73,95%CI 2.00-3.73, P < 0.001, I2 = 78.2%; HR=1.43, 95%CI 1.28-1.61, P < 0.001, I2 = 16.3%, respectively). Also, for 1873 patients receiving chemotherapy, a poor LIPI score was significantly associated with worse OS (HR=2.30, 95%CI 1.73-3.07, P < 0.001; I2 = 56.2%) and PFS (HR=1.92,95%CI 1.69-2.17; P < 0.001; I2 = 0.0%) compared with good LIPI score groups.ConclusionsA good LIPI score was significantly correlated with improved OS and PFS in cancer patients receiving ICIs or chemotherapy, regardless of the types of cancer.

【 授权许可】

Unknown